These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11121835)

  • 1. Pharmacological chaperones: a new twist on receptor folding.
    Morello JP; Petäjä-Repo UE; Bichet DG; Bouvier M
    Trends Pharmacol Sci; 2000 Dec; 21(12):466-9. PubMed ID: 11121835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
    Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
    Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical chaperones: mechanisms of action and potential use.
    Papp E; Csermely P
    Handb Exp Pharmacol; 2006; (172):405-16. PubMed ID: 16610368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
    Robben JH; Deen PM
    BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.
    Mouillac B; Mendre C
    Handb Exp Pharmacol; 2018; 245():63-83. PubMed ID: 28939971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein.
    Brown CR; Hong-Brown LQ; Biwersi J; Verkman AS; Welch WJ
    Cell Stress Chaperones; 1996 Jun; 1(2):117-25. PubMed ID: 9222597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones.
    Tamarappoo BK; Verkman AS
    J Clin Invest; 1998 May; 101(10):2257-67. PubMed ID: 9593782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxycycline and protein folding agents rescue the abnormal phenotype of familial CJD H187R in a cell model.
    Gu Y; Singh N
    Brain Res Mol Brain Res; 2004 Apr; 123(1-2):37-44. PubMed ID: 15046864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
    Mouillac B; Mendre C
    Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological chaperones: a potential therapeutic treatment for conformational diseases].
    Mendre C; Mouillac B
    Med Sci (Paris); 2010; 26(6-7):627-35. PubMed ID: 20619166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease.
    Amaral MD
    J Inherit Metab Dis; 2006; 29(2-3):477-87. PubMed ID: 16763920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
    Morello JP; Salahpour A; Laperrière A; Bernier V; Arthus MF; Lonergan M; Petäjä-Repo U; Angers S; Morin D; Bichet DG; Bouvier M
    J Clin Invest; 2000 Apr; 105(7):887-95. PubMed ID: 10749568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical chaperones mitigate experimental asthma by attenuating endoplasmic reticulum stress.
    Makhija L; Krishnan V; Rehman R; Chakraborty S; Maity S; Mabalirajan U; Chakraborty K; Ghosh B; Agrawal A
    Am J Respir Cell Mol Biol; 2014 May; 50(5):923-31. PubMed ID: 24299608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism.
    Robben JH; Sze M; Knoers NV; Deen PM
    Mol Biol Cell; 2006 Jan; 17(1):379-86. PubMed ID: 16267275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological chaperones: potential treatment for conformational diseases.
    Bernier V; Lagacé M; Bichet DG; Bouvier M
    Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH; Sze M; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue of a nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutant by cell-penetrating peptides.
    Oueslati M; Hermosilla R; Schönenberger E; Oorschot V; Beyermann M; Wiesner B; Schmidt A; Klumperman J; Rosenthal W; Schülein R
    J Biol Chem; 2007 Jul; 282(28):20676-85. PubMed ID: 17491025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics.
    Mendre C; Mouillac B
    Adv Protein Chem Struct Biol; 2019; 118():249-272. PubMed ID: 31928727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.
    Ulloa-Aguirre A; Michael Conn P
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan; 5(1):13-24. PubMed ID: 22074574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.